Dropless vitrectomy for vitreous hemorrhage controls intraocular inflammation
Click Here to Manage Email Alerts
A form of dropless vitrectomy helped control intraocular inflammation and prevent infection after surgery for vitreous hemorrhage secondary to proliferative diabetic retinopathy, according to a study.
In a presentation at the American Society of Retina Specialists meeting, K.V. Chalam, MD, PhD, MBA, FASRS, said his center has been performing dropless cataract surgery for about 6 years with good success rates.
“For 3 or 4 years, we have been doing vitrectomy surgery as well,” he said.
Chalam and colleagues conducted a retrospective chart review that included 412 consecutive patients. One group of patients underwent vitrectomy surgery for vitreous hemorrhage with a single injection of triamcinolone acetonide-moxifloxacin (Tri-Moxi, ImprimisRx), while a second group underwent the same surgery with a standard topical regimen of steroid-antibiotic eye drops.
Rate of infection, rate of IOP, degree of intraocular inflammation, OCT thickness, visual acuity and resolution of vitreous hemorrhage were compared between the two groups.
Chalam said there were no infections in either group, and the IOP rate was similar. Additionally, visual acuity, resolution of vitreous hemorrhage and cellular reaction were comparable between the two groups.
Tri-Moxi can be an inexpensive but effective method to control inflammation and avoid infection after vitrectomy in patients with vitreous hemorrhage, according to the study presentation.
Collapse
Chalam KV. ‘Dropless vitrectomy surgery’ for vitreous hemorrhage secondary to proliferative diabetic retinopathy. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.
Click Here to Manage Email Alerts